PRISMA Diagram for Gray Literature. This figure depicts the PRISMA Diagram for Identified Gray Literature. For regulatory information, FDA website was searched for 510(k) summaries for commercially FDA approved procalcitonin assays. The search yielded three 510(k) summaries for procalcitonin assay. Citations in the summary documents were screened against the main bibliographic databases. No new studies were identified from this source. Four clinical trial registries were searched. These were clinicaltrials.gov, current controlled trials, clinical study results and WHO clinical trials. This search yielded 91 studies. Of these, 47 studies were duplicate, 16 were ongoing and 26 met the exclusion criterion and therefore these 89 references were excluded. Remaining 2 articles were included after a full text review. Six sources for conference abstracts and papers were searched for the gray literature. They were conference papers index or CSA, Scopus, annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy or ICAAC, annual meeting of Infectious Diseases Society of America or IDSA, annual meeting of American College of Chest Physicians or ACCP and annual meeting of Pediatric Academic Societies or PAS. The search of these sources yielded 450 citations. Of these, 183 references were duplicate and 264 studies met the exclusion criterion and therefore these 447 references were excluded. Of the remaining 3 references- 2 were further excluded as full text article was unpublished and 1 was included after full-text review. Three sources for grants and federally funded research were searched. The first was NIH RePORTER, which is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other research institutions. The second was HSRPROJ, which is a database providing access to ongoing grants and contracts in health services research. The third was AHRQ GOLD, which is an online searchable database of AHRQ grants, working papers and HHS recovery act projects. The search of all 3 databases yielded 3 citations and all were excluded as they met the exclusion criterion. For identifying gray literature in the manufacturer database, the scientific information packets or SIPs was reviewed. The SIPs supplied by Thermo Fisher Scientific contained 67 published references or listings of clinical trials with abstracts. Of these 52 were duplicate and 12 met the exclusion criterion and one study could not be retrieved. Therefore these 67 references were excluded. Remaining 2 references were reviewed in full-text. One was excluded as it met the exclusion criterion and remaining study was included in the report. Overall the gray literature search resulted in 4 new relevant references to inform this review.

Figure 3PRISMA diagram for identified gray literature

ACCP = American College of Chest Physicians; AHRQ GOLD = Agency for Healthcare Research and Quality Grants On-Line Database; CSA = database at www.csa.com; FDA = Food and Drug Administration; HSRPROJ = Health Services Research Projects in Progress; ICAAC = Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; IDSA = Infectious Diseases Society of America; PAS = Annual meeting of Pediatric Academic Societies; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RePORTER = Research Portfolio Online Reporting Tools; WHO = World Health Organization

From: Results

Cover of Procalcitonin-Guided Antibiotic Therapy
Procalcitonin-Guided Antibiotic Therapy [Internet].
Comparative Effectiveness Reviews, No. 78.
Soni NJ, Samson DJ, Galaydick JL, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.